Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Quoin Pharmaceuticals  / Equity Bottom-Up

<ul><li>Between cash on hand and a recent arrangement for an equity line of credit for up to $8M, management believes that through its measures, it has extended its cash to maintain activities into late 2025.</li><li>This is expected to enable Quoin to continue moving QRX003 ahead through NS clinical trials and recent FDA clearance to recruit subjects 14 and older also allows Quoin to broaden the pool of people eligible to participate in the studies and thereby facilitate recruitment efforts.</li><li>Expanding the number of participants to an aggregate of 50 NS subjects also is expected to contribute to a more robust database to present for potential regulatory approval.</li></ul>

Between cash on hand and a recent arrangement for an equity line of credit for up to $8M, management believes that through its measures, it has extended its cash to maintain activities into late 2025.This is expected to enable Quoin to continue moving QRX003 ahead through NS clinical trials and recent FDA clearance to recruit subjects 14 and older also allows Quoin to broaden the pool of people eligible to participate in the studies and thereby facilitate recruitment efforts.Expanding the number of participants to an aggregate of 50 NS subjects also is expected to contribute to a more robust database to present for potential regulatory approval.

QNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 Approvals